Literature DB >> 27483487

Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Ergul Berber1, Mehmet Ozbil1, Christine Brown2, Zafer Baslar3, S Hande Caglayan4, David Lillicrap2.   

Abstract

BACKGROUND: Abnormalities in the biosynthetic pathway or increased clearance of plasma von Willebrand factor (VWF) are likely to contribute to decreased plasma VWF levels in inherited type 1 von Willebrand disease (VWD). Recent studies demonstrated that 65% of type 1 VWD patients have candidate VWF mutations, the majority of which are missense variants. The purpose of this study was to explore the effects of three VWF missense mutations (p.M771I, p.L881R and p.P1413L) located in different functional domains of VWF, reported as candidate mutations in type 1 VWD patients in the course of the MCMDM-1VWD study.
MATERIALS AND METHODS: The focus of these studies was on the intracellular biosynthetic processing and localisation of VWF in a heterologous cell system. Molecular dynamic simulation for p.M771I and p.P1413L was also performed to analyse the conformational effects of the changes.
RESULTS: As determined by immunofluorescence antibody staining and confocal microscopy of HEK293 cells, the intracellular localisation of recombinant VWF with the p.M771I variation was impaired. Transient transfection studies and phorbol myristate acetate stimulation in COS-7 cells revealed significant intracellular retention. In addition, major loss of VWF multimers was observed for only the p.M771I mutation. Molecular dynamic simulations on p.M771I mutant VWF revealed distinct structural rearrangements including a large deviation in the E' domain, and significant loss of β-sheet secondary structure. DISCUSSION: The pathogenic effects of candidate VWF gene mutations were explored in this study. In vitro expression studies in heterologous cell systems revealed impaired secretion of VWF and a dominant negative effect on the processing of the wild-type protein for only the p.M771I mutation and none of the mutations affected the regulated secretion.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27483487      PMCID: PMC5649964          DOI: 10.2450/2016.0034-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  29 in total

1.  An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.

Authors:  E Berber; P D James; C Hough; D Lillicrap
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

2.  Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.

Authors:  G Castaman; S H Giacomelli; P M Jacobi; T Obser; U Budde; F Rodeghiero; R Schneppenheim; S L Haberichter
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

3.  Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.

Authors:  I Bodó; A Katsumi; E A Tuley; J C Eikenboom; Z Dong; J E Sadler
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

5.  An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Authors:  Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

6.  Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.

Authors:  Lee A O'Brien; Paula D James; Maha Othman; Ergul Berber; Cherie Cameron; Colleen R P Notley; Carol A Hegadorn; Jeffrey J Sutherland; Christine Hough; Georges E Rivard; Denise O'Shaunessey; David Lillicrap
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 7.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

8.  The effect of ABO blood group on the diagnosis of von Willebrand disease.

Authors:  J C Gill; J Endres-Brooks; P J Bauer; W J Marks; R R Montgomery
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

9.  Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).

Authors:  U Budde; R Schneppenheim; J Eikenboom; A Goodeve; K Will; E Drewke; G Castaman; F Rodeghiero; A B Federici; J Batlle; A Pérez; D Meyer; C Mazurier; J Goudemand; J Ingerslev; D Habart; Z Vorlova; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2008-03-01       Impact factor: 5.824

Review 10.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  2 in total

1.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

Review 2.  Von Willebrand Disease: From In Vivo to In Vitro Disease Models.

Authors:  Suzan de Boer; Jeroen Eikenboom
Journal:  Hemasphere       Date:  2019-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.